VEGFA and neoplasm: The advent of tyrosine kinase inhibitor (TKI) as effective therapy for metastatic RCC resulted from discovery that disruption of the vascular endothelial growth factor (VEGF) signaling pathway can retard tumor growth and progress.[2] Sunitinib has inhibitory effect on many receptor kinases such as VEGF receptors and platelet derived growth factor (PDGF) receptors.